Tag: OPPI
Budget 2025: OPPI hails initiatives for inclusive & innovation-driven healthcare landscape
Anil Matai, Director General, OPPI expresses commitment towards working alongside policymakers to further strengthen the sector and address areas that require continued attention
Budget 2025: OPPI seeks special incentives
Policy-level clarifications, such as expanded exemptions for life-saving drugs and oncology medications from import duty are vital for reducing treatment costs
Bhushan Akshikar appointed as OPPI President
Bhushan is the Vice President & Managing Director of GSK (GlaxoSmithKline Pharmaceuticals) India
OPPI welcomes Indian govt’s move to waive off local clinical trials...
This will be applicable to a few select drugs already approved in well-regulated markets like the USA, UK, Japan, Australia, Canada, and the EU
Budget 2024 reflects a forward-looking and inclusive approach: Anil Matai, DG,...
Anil Matai, Director General, Organisation of Pharmaceutical Producers of India (OPPI) appreciated the positive strides yet also emphasized that the government could have announced incentives for pharma companies to develop medications for rare diseases
Budget 2024: OPPI seeks concessional tax rates for pharma players engaged...
The leading association has also demanded elimination of import duties on life-saving drugs
OPPI Annual Summit: Stakeholders discuss roadmap to shape the future of...
The theme for this year’s Summit ‘Bharat Ke Liye’ encapsulated its commitment to converge and collaborate with stakeholders to co-create innovative solutions to address the nation’s healthcare challenges
India’s healthcare & pharma leaders set sight on disruptive innovation by...
Need for a resilient innovation ecosystem to foster collaborative engagement between stakeholders
OPPI appoints Anil Matai as Director-General
Anil Matai, a seasoned general management professional, has extensive experience in the Life Sciences space having worked across MNCs
OPPI organizes two-day ‘Innovate India Vision 2047’ Conference in New Delhi
The conference in association with Department of Pharmaceuticals (DoP) created an environment for knowledge exchange, deliberation, and collaboration